Page 361 - Binder2

This Isn’t a Silver Bullet—It’s a Shift in Terrain

No one is claiming that edible biologics will replace all
injectables. There are diseases, delivery contexts, and
pharmacokinetics where IV or subcutaneous delivery will
remain necessary and appropriate.

But for a massive and growing category of therapies—
enzymes, antibodies, tolerizing agents, cytokine
mimetics, oral vaccines, and mucosal immune
modulators—edible biologics represent not just a viable
alternative, but a superior platform:

● Cheaper to produce
● Simpler to scale
● Shelf-stable and cold-chain independent
● More accessible to low-resource settings
● Capable of reducing immune rejection through
mucosal tolerance

And that changes everything.

From Fortress to Network

As this model takes root, the fortress model of pharma
begins to look less like a necessity and more like an
artifact—a relic of a time when complexity was the cost
of control.

But now?

● Therapies can be grown, not synthesized.
● Manufacturing can be distributed, not centralized.

359